Scientific Advances and the Fight Against AIDS
AIDS Blog, July 19, 2011--This week, I am in Rome, Italy, for the International AIDS Society’s Conference on HIV Pathogenesis, Treatment, and Prevention. This gathering of researchers caps a year of incredible scientific announcements, and I anticipate even more at this meeting.
Last summer, the PEPFAR-funded CAPRISA study of a tenofovir-based microbicide demonstrated successful proof-of-concept for this female controlled prevention method. The study showed that women using the microbicide gel had an average of 39 percent fewer HIV infections and 51 percent fewer genital herpes infections compared to women who used a placebo gel. The results of this study were clear evidence of the importance of U.S. investments — across multiple agencies — in microbicides. And through PEPFAR, our country teams will be working to create the regulatory path and client demand for these products when they are ready to be marketed, so that this innovation can be quickly brought to bear in order to save lives.
Email This Page
Share This Page
